

79

EFFECT OF SALT LOADING ON CARDIOVASCULAR RESPONSE TO MENTAL STRESS IN ADOLESCENTS. Falkner, B., Onesti, C., Gould, A., Hayes, P. Hahnemann Medical College, Phila., Pa., U.S.A.

The effects of salt loading on the cardiovascular response to mental stress was compared between 8 adolescents with high genetic risk (Genetic group) for essential hypertension (hypertensive parents) and 8 adolescents with low risk (Control group) (normotensive parent). Systolic (S), Diastolic (D) pressure and heart rate (HR) were monitored (Arteriosonde) at 1 minute intervals during difficult mental arithmetic. Plasma catecholamines (CA) were determined before and after stress. Subjects then consumed 10gm/day Na Cl in excess of usual diet for 14 days. Mental stress and CA were then repeated. Measurement of urine Na confirmed high salt intake. A greater cardiovascular response (greater increase in S, D, and HR) was seen in Genetic group compared to Control ( $p < .01$ ). Salt loading increased BP, augmented the high D responses and suppressed CA in the Genetic group. Salt loading produced no change in BP or CA in Controls. Concl: Genetic adolescents have a higher cardiovascular response to mental stress. Some genetic adolescents are salt sensitive. Control adolescents are salt resistant.

80

CHANGES IN RENAL FUNCTION AND MORPHOLOGY IN STREPTOZOTOCIN (STZ) AND PANCREATICTOMIZED (PX) RHESUS MONKEYS (RM). John EG, Manaligod J, Miller J, Jonasson O,

Univ. of Ill. and Cook County Hosp. Dept. of Pediatrics Anatomy and Surg. Chicago. U.S.A.

This study was undertaken to examine the degree of renal (R) functional and structural (S) involvement in STZ-Insulin (I) dependent (STZI, for 3-8 years; I requirement 2-7 U/day) or STZ carbohydrate disturbed (CHO, for 3-9 years) or Px (for 2-4 years; I, 2-7 U/day) model of diabetes (D) in RM. Glomerular filtration rate (GFR) renal plasma flow (RPF) urinary protein (UP) and kidney biopsy (BX) were done. Bx was evaluated by light microscopy (LM). In STZI and Px blood sugar ranged between 150-400mg%.

NO.	AGE	GFR		RPF		UP	HIST
		ml/min/kg	ml/min/kg	ml/min/kg	mg/24hr.		
CONTROL(C)29	6-17	2.21±.04	5.02±.24	30±14	0		
CHO	7	1.69±.19*	3.95±.52	113±57*	0		
STZ-I	7	2.09±.28	4.47±.50	118±50*	++		
Px	8	2.67±.14	5.94±.52	70±10*	++		

GFR and RPF was significantly low in CHO and normal in STZI compared to C. GFR and RPF was high in Px compared to C but not significant. There was significant proteinuria (P) in CHO, STZI, and Px. In 4/5 STZI and 3/5 Px LM change consisted of basement membrane thickening and increase in mesangial matrix. LM changes and P in STZI and Px suggest D nephropathy. This study also suggests that structural changes (SC) can precede R dysfunction e.g. STZ and Px or vice-versa e.g. CHO. Early I therapy did not prevent SC in STZ or Px, most probably due to inadequate D control. \* $p < .05$ .

## RENAL OSTEODYSTROPHY

81

PAEDIATRIC RENAL OSTEODYSTROPHY: Hodson, E. M.; Dunstan, C.R.; Hills, E.E.; Evans, R.A. Royal Alexandra Hospital for Children & Concord Hospital, Sydney, N.S.W., Australia.

To determine the prevalence of renal osteodystrophy 47 children, aged 1-17 yrs, with glomerular filtration rates (GFR)  $< 80 \text{ ml/min/1.73m}^2$  underwent bone biopsies after double tetracycline labelling. Histological parameters in undecalcified sections were measured by a digitizer interfaced to a computer. Control data was from 9 children, aged 1-14 yrs. Hyperparathyroid bone disease (HPD) & osteomalacia (OM) were diagnosed by increases in resorbing surface & decreases in mineralization front respectively. In group 1 (GFR  $> 30 \text{ ml/min/1.73m}^2$ ; 16 children), 4 children had increased osteoid surfaces. Changes in other histological parameters were not seen. In group 2 (GFR 20-29  $\text{ml/min/1.73m}^2$ ), 3 children had HPD. In group 3 (GFR  $< 20 \text{ ml/min/1.73m}^2$ ; 23 children), 12 children had HPD, 2 OM & 9 mixed disease (MD). X-rays & alkaline phosphatase levels were normal in 10 children with histological changes (HPD 6, OM 1, MD 3). Parathyroid hormone levels were elevated in 22 children with & 10 without histological changes. Serum calcium, phosphorus & bicarbonate did not correlate with any histological parameters. Thus renal bone disease was only seen in children with GFRs  $< 30 \text{ ml/min/1.73m}^2$  & was only reliably diagnosed by bone biopsy.

82

SERUM 1,25-DIHYDROXYVITAMIN D (1,25-(OH)<sub>2</sub>D) LEVELS IN CHILDHOOD RENAL DISEASE. Chesney, R.W., Hamstra, A.J. and DeLuca, H.F. The University of Wisconsin, Madison Wisconsin, USA.

The renal 1 $\alpha$ -hydroxylation of vitamin D yields 1,25-(OH)<sub>2</sub>D, the hormonally active form of the vitamin. Serum levels are markedly reduced in uremic children with demineralization and osteodystrophy (Chesney et al Am J Dis Child 134:135,1980). Using a precise assay, we have measured serum 1,25-(OH)<sub>2</sub>D in 27 children with various glomerular (n=15) and tubular (n=12) diseases, not treated with steroids which reduce 1,25-(OH)<sub>2</sub>D (Chesney et al Lancet II,1123,1978). Serum was obtained in the fasting state on usual diet. Levels were compared to age-matched controls (2-16 yr) and in terms of creatinine clearance using the Schwartz formula based on height and serum creatinine.

Group	(n)	1,25-(OH) <sub>2</sub> D, pg/ml	Range
Normal controls	116	43 ± 2 <sup>2</sup> (SE)	12-111
Renal disease			
97 ± 7 (SE) ml/min/1.73M <sup>2</sup>	10	47 ± 7	20-75
32 ± 3 ml/min/1.73M <sup>2</sup>	7	22 ± 5	0-37
10 ± 2 ml/min/1.73M <sup>2</sup>	10	13 ± 4	0-27

Patients with clearances  $> 50 \text{ ml/min}$  have values not different from normal; from 25-50  $\text{ml/min}$  (mean 32) have significant reduction compared to controls ( $p < .01$ ) and below 25  $\text{ml/min}$  have greatly reduced values ( $p < .001$ ). This data suggests that defective production of 1,25-(OH)<sub>2</sub>D begins at  $\approx 35 \text{ ml/min/1.73M}^2$  and may be important in the high incidence of osteodystrophy found in children.

83

RENAL OSTEODYSTROPHY IN CHILDREN: THERAPY WITH VITAMIN D<sub>3</sub> OR 1,25-DIHYDROXY-CHOLECALCIFEROL (1,25-DHCC) Bulla, M., Delling, G., Offermann, G., Ziegler, R.

Kinderklinik Universität Köln; Institut für Pathologie der Universität Hamburg; Med.Klinik + Poliklinik FU Berlin; Abt.f. Endokrinologie, Zentrum Innere Medizin u. Kinderheilkunde, Universität Ulm, FRG

Growth arrest and renal osteodystrophy is a major problem in renal insufficiency of children. The present report describes our experiences in managing renal osteodystrophy in 16 children on maintained hemodialysis treatment by using vitamin D<sub>3</sub> for 12 to 18 months and in 14 dialyzed children by using 1,25-DHCC for 12 months. In treatment with vitamin D<sub>3</sub> plasma-Ca, alkaline phosphatase and iPTH normalized nearly. Radiographic abnormalities improved. Bone biopsies showed improvement in signs of secondary hyperparathyroidism and otitis fibrosa, whereas osteomalacia remained unchanged and osteoblast population showed a small reduction. No real increment in body growth was seen. In treatment with 1,25-DHCC alkaline phosphatase and iPTH normalized completely. Radiographic examinations revealed marked improvement. Histological signs of fibroosteoclasia and resorptive defects disappeared but there was no recovery of osteomalacia. A reduction of osteoblast population and of bone transformation was obvious. 1,25-DHCC, also, failed to normalize growth in uremic children. Summarizing, neither vitamin D<sub>3</sub> nor 1,25-DHCC can guarantee complete recovery of renal osteodystrophy and growth arrest in uremic children.

84

EFFECT OF VITAMIN D<sub>3</sub> AND 1,25(OH)<sub>2</sub>D<sub>3</sub> ON GROWTH IN EXPERIMENTAL UREMIA (EU) Gilli, G., Ritz, E., Mehls, O., v.d. Linden, A.

University Children's Hospital, Heidelberg, F.R.G.

Growth retardation is a major unsolved problem in children with chronic renal failure. A stimulatory effect of D<sub>3</sub> on growth rate in EU has been demonstrated (Mehls et al., Am.J.Clin.Nutr., 1978), but clinical results are conflicting. Chesney et al. (New Eng.J.Med., 1978) reported increased growth velocity in uremic children treated by 1,25(OH)<sub>2</sub>D<sub>3</sub> who had failed to respond to high dosage D<sub>3</sub>. The present study was designed to compare the efficacy of D<sub>3</sub> and 1,25(OH)<sub>2</sub>D<sub>3</sub> (3-point dose response curve) on growth in rats with EU. Methods: 90g male Sprague-Dawley rats with stable uremia (2-stage subtotal nephrectomy) of 3 weeks' duration (C<sub>0</sub> 18% of normal). All animals fed ad lib. Five groups: I NX solvent; II and III NX + D<sub>3</sub> (0.5 and 1.0  $\mu\text{g}/70\text{g/day}$ ); IV and V: NX + 1,25(OH)<sub>2</sub>D<sub>3</sub> (0.625 and 1.25  $\text{ng}/70\text{g/day}$ ). Results: Serum Ca increased ( $p < 0.01$ ) to the same extent in III and V. In comparison to not treated animals (I), growth rate was significantly better in III and V for both weight (III and V:  $p < 0.01$ ) and length (III and V:  $p < 0.05$ ), but there was no difference between III and V. Conclusion: The present study cannot confirm that 1,25(OH)<sub>2</sub>D<sub>3</sub> has a more beneficial effect on growth than vitamin D<sub>3</sub>.